-
1 Comment
Magenta Therapeutics, Inc is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Magenta Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 21.8% to $-18M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.6% to $-14M since the same quarter in the previous year.
Based on the above factors, Magenta Therapeutics, Inc gets an overall score of 3/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for MGTA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
